| Urinary excretion of carnitine as a marker of proximal tubular damage associated with platin-based antineoplastic drugs. | |
| | |
MedLine Citation:
|
PMID: 19736245 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Patients treated with cisplatin or carboplatin show increased renal excretion of carnitine. It is currently unclear whether this is also the case for oxaliplatin and which are the responsible mechanisms. METHODS: We investigated 22 patients treated either with a single dose of cisplatin, carboplatin or oxaliplatin. Carnitine and kidney function parameters were determined in plasma and urine. Inhibition and mRNA expression of OCTN2, the principle carnitine transporter, were assessed in L6 cells overexpressing OCTN2 and in 293-EBNA cells, respectively. RESULTS: Renal excretion of free and short-chain acylcarnitine increased already at the day of administration was maximal the day after and had normalized 1 week after administration of cisplatin, carboplatin or oxaliplatin. The renal excretion fractions for free carnitine and acylcarnitines increased 4-10 times during treatment with platin derivatives. Renal excretions of alpha1-microglobulin and other proximal tubular markers were also increased, compatible with a proximal tubular defect. Direct inhibition of OCTN2 expressed in L6 cells by cisplatin, oxaliplatin or platinum(2+) could not be demonstrated, and experiments using urine from patients treated with cisplatin inhibited OCTN2 activity no more than expected from the carnitine content in the respective urine sample. Cisplatin was associated with a time- and concentration-dependent decrease of OCTN2 mRNA and protein expression in 293-EBNA cells. CONCLUSIONS: All platin derivatives investigated are associated with renal tubular damage in humans without significantly affecting glomerular function. The rapid onset and complete reversibility of this effect favour a functional mechanism such as impaired expression of OCTN2 in proximal tubular cells. |
| | |
Authors:
|
Manuel Haschke; Tanja Vitins; Saskia L?de; Liliane Todesco; Katerina Novakova; Richard Herrmann; Stephan Kr?henb?hl |
Related Documents
:
|
10803735 - Mechanisms by which intrarenal dopamine and anp interact to regulate sodium metabolism. 15163425 - Hsv excretion after bone marrow transplantation: a 4-year survey. 17560155 - Acute and chronic effects of growth hormone on renal regulation of electrolyte and wate... 1436285 - Amino-aciduria and enzymuria in patients with artificial heart valves. 8089635 - Angiotensin converting enzyme inhibitor and chronic renal failure. 1670905 - Etiology and pathophysiology of pyelonephritis. |
Publication Detail:
|
Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't Date: 2009-09-07 |
Journal Detail:
|
Title: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association Volume: 25 ISSN: 1460-2385 ISO Abbreviation: Nephrol. Dial. Transplant. Publication Date: 2010 Feb |
Date Detail:
|
Created Date: 2010-01-22 Completed Date: 2010-05-19 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8706402 Medline TA: Nephrol Dial Transplant Country: England |
Other Details:
|
Languages: eng Pagination: 426-33 Citation Subset: IM |
Affiliation:
|
Division of Clinical Pharmacology & Toxicology and Department of Biomedicine, University Hospital, Switzerland. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Antineoplastic Agents / adverse effects* Biological Markers / urine* Carboplatin / therapeutic use* Carnitine / urine* Cells, Cultured Cisplatin / adverse effects* Female Humans Kidney Diseases / chemically induced* Kidney Tubules, Proximal* / metabolism Male Middle Aged Organic Cation Transport Proteins / biosynthesis Organoplatinum Compounds / therapeutic use* |
| Chemical | |
Reg. No./Substance:
|
0/Antineoplastic Agents; 0/Biological Markers; 0/Organic Cation Transport Proteins; 0/Organoplatinum Compounds; 0/SLC22A5 protein, human; 15663-27-1/Cisplatin; 41575-94-4/Carboplatin; 541-15-1/Carnitine; 63121-00-6/oxaliplatin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Exercise capacity and body composition in living-donor renal transplant recipients over time.
Next Document: Effect of MCI-196 on serum phosphate and cholesterol levels in haemodialysis patients with hyperphos...